SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) — Shareholder Rights Law Firm Johnson Fistula, LLP announces that a class action lawsuit has been commenced on behalf of investors in Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). The class action is being brought on behalf of shareholders who purchased or otherwise acquired Fulgent shares between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”). Investors are hereby notified that they have until November 21, 2022 to request the court to appear as lead plaintiff in this lawsuit.

What actions can I take at this time? If you have suffered a loss and would like to learn more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. When emailing, please include your phone number.

To participate in this promotion you can click on the following link or copy and paste it into a browser:

https://www.cognitoforms.com/JohnsonFistel/Fulgent Genetics Inc

There are no costs or obligations for you.

Fulgent Genetics’ class action lawsuit alleges that the defendants failed to disclose that: (i) Fulgent Genetics performed medically unnecessary laboratory testing, engaged in improper billing practices related to laboratory testing, and paid or received compensation in violation of the Anti-Kickback statute and Stark Law; (ii) accordingly, Fulgent Genetics would likely be subject to increased legal and regulatory scrutiny; (iii) Fulgent Genetics’ earnings, to the extent derived from the foregoing unlawful conduct, were unsustainable; and (iv) the foregoing, once disclosed, would be likely to subject Fulgent Genetics to material financial and/or reputational damage.

A lead plaintiff will act on behalf of all other group members in directing Fulgent’s class action. The lead plaintiff may select a law firm of its choice to conduct the class action. An investor’s ability to share a potential future recovery of the Fulgent…